EvoNext Holdings Ltd, previously Evolva Holding Ltd, is a Switzerland-based Company operating as a researcher for biotechnology. The Company develops and commercializes nature-based ingredients. The ingredients, produced by the Company, can be employed in, but not limited to, flavorings fragrancies, health ingredients, health protection and other various sectors. The objectives of the Company are as follows: develop technology platforms - combines biology with technology to produce nature-based ingredients; provide technology services- provides tailored services to clients across industries. The Company is focused on developing and increasing the return and effectiveness of the production of numerous ingredients within their portfolio.

Employees

Sector

Biotechnology & Medical Research

More about the company

30/04	EvoNext Holdings SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
21/25/21	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI

Market Cap	1.25Cr 1.55Cr 1.36Cr 1.17Cr 2.2Cr 146.71Cr 2.21Cr 15Cr 5.8Cr 72Cr 5.83Cr 5.7Cr 250.58Cr	P/E 2024	6.22x	P/E 2025	-8.95x
Enterprise Value	66.42L 82.18L 71.81L 62L 1.16Cr 78Cr 1.17Cr 7.89Cr 3.07Cr 38Cr 3.09Cr 3.02Cr 132.65Cr	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	58.74%	Yield 2024 *	-	Yield 2025	-

30/04	EvoNext Holdings SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
21/25/21	EvoNext Holdings SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25/25/25	Evolva Shareholders OK Proposed Renaming to EvoNext	MT
25/25/25	Evolva Holding SA has Changed its Name to EvoNext Holdings SA	CI
23/25/23	Evolva to Not Receive Earn-out Payments from Unit's Buyer	MT
03/25/03	Evolva Directors Propose Change of Name to EvoNext	MT
04/25/04	Evolva Seeks Dialogue with Swiss Hospital Shareholders on Takeover Bid	MT
27/25/27	Evolva Offers to Buy Hospital in Switzerland	MT
21/25/21	Evolva Swings to FY24 Net Profit	MT
21/25/21	Evolva Holding SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
21/25/21	Evolva Holding SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
04/25/04	Evolva Holding: Shareholder Clearway Requests General Meeting	RE
30/24/30	Swiss Stocks Close Higher Ahead of New Year Break	MT

20/05	EvoNext : Minutes of Annual General Meeting 2026	PU
20/05	EvoNext shareholders approve all motions proposed by the Board at the Annual General Meeting 2026	EQ
29/04	EvoNext : Invitation to AGM 2026 E	PU
29/04	EvoNext : (2025 12 EvoNext Holdings SA Annual Report 2025)	PU
29/04	EvoNext Holdings SA publishes full-year report 2025	EQ

20/05	Evonext-Aktionäre stimmen an GV allen Anträgen zu
29/04	Evonext poursuit ses recherches, forte d'une assise financière solide
29/04	Evonext weist solide Kapitalbasis aus - Suche für Reverse Takeover läuft weiter
29/04	EvoNext : Einladung zur Generalversammlung 2026 DE
21/25/21	Evonext (ex-Evolva) a consumé des liquidités au premier semestre

ARPIDA Share Price Swiss Exchange

Stocks

ARPN

Biotechnology & Medical Research

Valuation: ARPIDA

Latest news : ARPIDA

Analysts' recommendations: ARPIDA

Press Releases: ARPIDA

News in other languages: ARPIDA

Managers and Directors: ARPIDA

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Francesco Defila BRD	Director/Board Member	-	27/03/2025
Gianluca Ferrari CHM	Chairman	-	27/03/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.34%	+2.06%	-10.67%	-5.26%	4.31TCr
REVOLUTION MEDICINES, INC.	+1.73%	+7.76%	+318.08%	+543.17%	3.47TCr
BEONE MEDICINES AG	+0.61%	+2.77%	+10.00%	+46.44%	3TCr
IQVIA HOLDINGS INC.	+0.02%	-7.52%	+8.45%	-21.52%	2.8TCr
CELLTRION, INC.	-1.06%	-2.60%	+9.08%	+21.51%	2.44TCr
ASCENDIS PHARMA A/S	-1.23%	+4.56%	-	-	1.43TCr
MEDPACE HOLDINGS, INC.	-0.99%	-2.50%	+47.29%	+106.70%	1.31TCr
EUROFINS SCIENTIFIC SE	+1.54%	-0.94%	+6.69%	+8.40%	1.25TCr
IONIS PHARMACEUTICALS, INC.	+2.39%	+3.57%	+102.86%	+83.89%	1.22TCr
Average	+0.20%	+0.65%	+61.47%	+97.92%	2.36TCr
Weighted average by Cap.	+0.16%	+1.19%	+67.04%	+113.26%

	2024	2025
Net sales	-	-
Net income	10.44L 12.91L 11.28L 10L 18.29L 12Cr 18.42L 1.24Cr 48.26L 6Cr 48.49L 47.44L 21Cr	-7L -8L -7L -6L -11.44L -7.63Cr -11.52L -77.56L -30.18L -3.75Cr -30.32L -29.66L -13Cr
Net Debt	-67.53L -83.55L -73.01L -63.03L -1.18Cr -79Cr -1.19Cr -8.03Cr -3.12Cr -39Cr -3.14Cr -3.07Cr -134.86Cr	-59.06L -73.07L -63.84L -55.12L -1.03Cr -69Cr -1.04Cr -7.02Cr -2.73Cr -34Cr -2.74Cr -2.68Cr -117.93Cr

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-